Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Botulinum toxin as adjunctive therapy in refractory laryngeal granuloma 85th Annual Meeting of the American-Broncho-Esophagological-Association Damrose, E. J., Damrose, J. F. CAMBRIDGE UNIV PRESS. 2008: 824–28

Abstract

This study evaluated the role of botulinum toxin type A in the treatment of refractory laryngeal granulomas.Retrospective clinical review at a tertiary care hospital. Seven patients with vocal process granulomas underwent percutaneous injection of botulinum toxin into both vocal folds, performed in an office setting. Total doses ranged from 10 to 25 U, divided between both vocal folds.All patients experienced resolution of their granulomas over two to seven weeks. No patient developed aspiration pneumonia. All patients experienced hoarseness secondary to the injections, but voice quality returned to baseline in all patients as the toxin was degraded.Botulinum toxin is safe and effective therapy in resolving vocal process granulomas in patients refractory to traditional therapy. The optimal treatment dose remains to be determined.Percutaneous botulinum toxin injection is helpful in resolving laryngeal granulomas.

View details for DOI 10.1017/S0022215107000710

View details for Web of Science ID 000258380000011

View details for PubMedID 17908354